

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

Alimta (pemetrexed disodium)

CG-DRUG-38

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Alimta (pemetrexed disodium)

APPROVAL CRITERIA

Requests for Alimta (pemetrexed disodium) **may be approved** for treatment of any of the following indications:

- I. Malignant mesothelioma when either of the following criteria are met:
 - A. As combination therapy with cisplatin or carboplatin; **OR**
 - B. As a first-line of therapy in combination with cisplatin or carboplatin and bevacizumab in individuals who meet all of the following criteria:
 1. Eastern cooperative Oncology Group performance status of 0-2; **AND**
 2. No history of hemoptysis or thrombosis; **AND**
 3. Unresectable disease presentation;

OR
- II. Locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC) when any of the following criteria are met:
 - A. As a single agent after prior chemotherapy; **OR**
 - B. As a first-line of therapy in combination with platinum-based chemotherapy; **OR**
 - C. As second-line therapy (first-line chemotherapy) in combination with platinum-based chemotherapy if tyrosine-kinase inhibitor (TKI)/anaplastic lymphoma kinase (ALK) targeted agent was given as first-line therapy;

OR
- III. As *maintenance therapy* for locally advanced or metastatic non-squamous NSCLC when disease has not progressed following four cycles of platinum-based, first-line therapy; **OR**
- IV. As a single-agent therapy for ovarian cancer for persistent disease or recurrence; **OR**
- V. As second-line therapy, and beyond, as a single-agent for metastatic urothelial carcinoma; **OR**
- VI. As second-line therapy, and beyond, as a single-agent for thymic cancer and thymomas.

Requests for Alimta (pemetrexed disodium) **may not be approved** when the above criteria are not met and for all other indications, including but not limited to:

- I. Primary central nervous system lymphoma (PCNSL);

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

II. Squamous cell non-small cell lung cancer;

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Alimta [Product Information], Indianapolis, IN. DailyMed. Updated September, 2015. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5a860f3-37ec-429c-ae04-9c88d7c55c08>. Accessed on October 01, 2017.

Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;(3):CD011430.

Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 Aug 14:[Epub ahead of print].

Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(30):3488-3515.

Pemetrexed Disodium (Alimta). In: DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated August 30, 2017. Available at: <http://www.micromedexsolutions.com>. Accessed on October 01, 2017.

Pemetrexed Disodium (Alimta). Monograph. Lexicomp® Online, American Hospital Formulary Service® (AHFS®) Online, Hudson, Ohio, Lexi-Comp., Inc. Last revised November 1, 2004. <http://online.lexi.com/lco/action/login>. Accessed on October 01, 2017.

National Cancer Institute (NCI). Pemetrexed Disodium. Last updated on October 25, 2011. Available at: <http://www.cancer.gov/cancertopics/druginfo/pemetrexedisodium>. Accessed on October 01, 2017.

NCCN Clinical Practice Guidelines in Oncology®. © 2017 National Comprehensive Cancer Network, Inc. For additional information: <http://www.nccn.org/index.asp>. Accessed on October 01, 2017

- Bladder Cancer (V5.2017). Revised May 25, 2017.
- Central Nervous System Cancers (V1.2017). Revised August 18, 2017.
- Malignant Pleural Mesothelioma (V2.2017). Revised July 07, 2017.
- Non-Small Cell Lung Cancer (V9.2017). Revised September 28, 2017.
- Ovarian Cancer (V3.2017). Revised August 30, 2017.
- Thymomas and Thymic Carcinomas (V1.2017). Revised March 02, 2017.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.